Received Feb 11, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | B9279 | — |
late second dose until January 15th 2025; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 70-year-old female patient who received HAB (Twinrix) (batch number B9279, expiry date 12-SEP-2026) for prophylaxis. Previously administered products included Twinrix (received 1st dose on 12-JUL-2024 with batch number 797F9 and lot expiry 30-DEC-2025). On 15-JAN-2025, the patient received the 2nd dose of Twinrix. On 15-JAN-2025, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: late second dose until January 15th 2025). The outcome of the drug dose administration interval too long was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: The pharmacist reported that a patient got their first dose of Twinrix and late second dose The patient received 2nd dose of Twinrix, later than the recommended interval, which led to lengthening of vaccination schedule.